HealthQuill Pharma
Illumina, Inc. will acquire California-based SomaLogic, a company that is involved in identifying and quantifying proteins within a cell, for $425 million, according to a company statement.
Drugs Health Pharma

Illumina to acquire proteomics company SomaLogic in $425 million all cash deal

HQ Team June 23, 2025: Illumina, Inc. will acquire California-based SomaLogic, a company that is involved in identifying and quantifying proteins within a.

Read More
Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants, showed patients lost about 23% of their body weight compared to a dummy group’s 2-3%.
Drugs Health Pharma

Novo Nordisk’s obesity drug CagriSema cuts weight by 23%

HQ Team June 22, 2025: Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants,.

Read More
Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, to gain access to a medicine to treat postpartum depression.
Drugs Health Pharma

Supernus Pharma to acquire Sage Therapeutics for $795 million all cash

HQ Team June 22, 2025: Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, as.

Read More
Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their weight in a small study, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s amycretin drug helps obese adults lose 24% weight

HQ Team June 21, 2025: Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their.

Read More
Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials in people with obesity compared to a dummy drug, the company stated.
Drugs Health Pharma

Wegovy’s weight-loss efficacy improves with higher dosage

HQ Team June 21, 2025: Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials.

Read More
Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an early-stage experimental therapy and to develop once-in-a-lifetime treatments for cardiovascular diseases.
Drugs Health Pharma

Eli Lilly to buy Verve for $1.3 billion, expands heart therapy segment

HQ Team June 19, 2025: Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an.

Read More
The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’ living cells to China and other “hostile countries” for the fear of genetic data misuse.
Drugs Health Pharma

US to review trials to stop genetic data misuse by China, ‘hostile’ nations

HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.

Read More
The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between 18 and 59 years.
Drugs Health Pharma

US regulator gives nod for Moderna’s expanded use of mRNA vaccine

HQ Team June 13, 2025: The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between.

Read More
Rein Therapeutics, Inc. has paused its enrollment and patient dosing at its US clinical trial sites testing a lung disease drug, after the regulator placed the experiment on clinical hold. 
Drugs Health Pharma

Rein Therapeutics’ trial drug for lung disease disorder put on clinical hold

HQ Team July 13, 2025: Rein Therapeutics, Inc., has paused its enrollment and patient dosing at its US clinical trial sites testing a.

Read More
UroGen Pharma Ltd.’s therapy to treat adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer has been approved by the US Food and Drug Administration.
Drugs Health Pharma

FDA approves UroGen’s muscle-invasive bladder cancer therapy

HQ Team June 13, 2025: UroGen Pharma Ltd.’s therapy to treat adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer has been.

Read More